AGER Antibodies

AGER antibodies are specialized antibodies designed to target and detect the advanced glycation end product-specific receptor (AGER), also known as RAGE (Receptor for Advanced Glycation End Products). RAGE is a cell surface receptor that belongs to the immunoglobulin superfamily and plays a crucial role in mediating cellular responses to various ligands, including advanced glycation end products (AGEs), S100 proteins, high mobility group box 1 (HMGB1), and amyloid-beta peptides. 

Content: RAGE is expressed in various tissues but is particularly abundant in the lungs. It can be upregulated in response to certain conditions, and its signaling can lead to pro-inflammatory responses:

• Diabetes Complications: AGEs are formed through non-enzymatic glycation of proteins and lipids, a process that is accelerated under hyperglycemic conditions. The interaction of AGEs with RAGE plays a key role in the development of diabetes complications, such as diabetic nephropathy, retinopathy, and atherosclerosis. 
• Cancer: RAGE expression is often upregulated in various cancers, where it contributes to tumor growth, metastasis, and angiogenesis. By promoting cell survival, proliferation, and migration, RAGE facilitates the progression of cancerous cells. AGER antibodies are used in cancer research to analyze RAGE expression in tumor tissues and to investigate its role in cancer cell signaling and metastasis.

Applications: AGER antibodies are widely used in various research and clinical applications, including:

• Western Blotting (WB): To detect and quantify RAGE protein levels in cell lysates or tissue extracts. Western blotting using AGER antibodies allows researchers to analyze changes in RAGE expression under various experimental conditions, including exposure to high glucose, pro-inflammatory cytokines, or oxidative stress. 
• Flow Cytometry: To analyze the expression of RAGE on the surface of cells. Flow cytometry with AGER antibodies can be used to quantify RAGE expression on different cell types, such as endothelial cells, macrophages, and cancer cells. 
• Research on RAGE-Targeted Therapeutics: AGER antibodies are used to investigate the potential of RAGE inhibitors as therapeutic agents. By blocking RAGE-ligand interactions, it is possible to reduce inflammation, prevent tissue damage, and inhibit cancer progression. 

AGER antibodies are essential tools in biomedical research and clinical diagnostics. They enable the study of RAGE's role in inflammation, metabolic disorders, cancer, and neurodegeneration, providing insights into the mechanisms by which RAGE contributes to disease progression.